Trial Design Likely Boosted Biogen (BIIB) BIIB037 Efficacy Data - Nomura
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Biogen Idec Presents Positive Interim Results from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at 2015 AD/PD™ Conference
March 20, 2015 5:35 AM EDTAnalysis Demonstrates Acceptable Safety, Statistically Significant Reduction of Amyloid Plaque Levels and Benefit on Exploratory Clinical Endpoints
Aducanumab Clinical Development Program to Advance to Phase 3
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Today Biogen Idec (NASDAQ: BIIB) announced data from a pre-specified interim analysis of PRIME, the Phase 1b study of aducanumab (BIIB037), in which aducanumab demonstrated an... More
